1. Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity
- Author
-
Edson Panganayi Sibanda, Bongiwe Ndlovu, Francisca Mutapi, Agness Farai Nhidza, Takafira Mduluza, Tawanda Chisango, Arthur Vengesai, and Danai Zhou
- Subjects
Male ,0301 basic medicine ,MDA ,Urine ,Adaptive Immunity ,Praziquantel ,Schistosomiasis haematobia ,0302 clinical medicine ,Medical microbiology ,Epidemiology ,Prevalence ,Schistosomiasis ,Longitudinal Studies ,030212 general & internal medicine ,Child ,Anthelmintics ,Immunoglobulin Isotypes ,Treatment Outcome ,Infectious Diseases ,Parasitic disease ,Schistosoma haematobium ,Female ,Research Article ,medicine.drug ,Zimbabwe ,medicine.medical_specialty ,Adolescent ,030106 microbiology ,Antibodies, Helminth ,Antibodies ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Pharmacotherapy ,Internal medicine ,parasitic diseases ,medicine ,Animals ,Humans ,lcsh:RC109-216 ,Hematuria ,Ovum ,business.industry ,Immunity ,medicine.disease ,Treatment ,Immunoglobulin G ,Tropical medicine ,business - Abstract
Background Schistosomiasis is a devastating parasitic disease. The mainstay of schistosomiasis control is by praziquantel treatment. The study aimed to determine benefits of annual chemotherapy of schistosomiasis on development of protective immunity in school children in a selected endemic rural area in Zimbabwe. Methods Urine specimens from 212 school children (7–13 years) were collected and examined to determine prevalence, intensity and reinfection of S.haematobium at baseline, 6 weeks and 2 years following annual rounds of praziquantel treatment. Blood samples from the participants were assayed for total and S. haematobium (Sh13)-specific antibodies before and 2 years after annual rounds of treatment. Results Annual treatment reduced the prevalence of S. haematobium infection (p
- Published
- 2019